Stacey Stauffer

Stacey Stauffer

Auto-generated profile, based on publicly available information

Stacey Stauffer

Laboratory of Cell and Developmental Signaling, Center for Cancer Research, NCI, Frederick, Maryland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2020 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
KBKajal Biswas
Kajal Biswas
GLGary B. Lipton
Gary B. Lipton
SSStacey Stauffer
Stacey Stauffer
TSTeresa Sullivan
Teresa Sullivan
LCLinda Cleveland
Linda Cleveland
SSShyam K. Sharan
Shyam K. Sharan
Sequencing-based genetic tests to identify individuals at increased risk of hereditary breast and ovarian cancers have resulted in the identification of more than 40,000 sequence variants of BRCA1 and BRCA2. A majority of these variants are considered to be variants of uncertain significance (VUS) because their impact on disease risk remains unknown, largely due to lack of sufficient familial linkage and epidemiological data. Several assays have been developed to examine the effect of VUS on protein function, which can be used to assess their impact on cancer susceptibility. In this study, we report the functional characterization of 88 BRCA2 variants, including several previously uncharacterized variants, using a well-established mouse embryonic stem cell (mESC)-based assay. We have examined their ability to rescue the lethality of Brca2 null mESC as well as sensitivity to six DNA damaging agents including ionizing radiation and a PARP inhibitor. We have also examined the impact of BRCA2 variants on splicing. In addition, we have developed a computational model to determine the probability of impact on function of the variants that can be used for risk assessment. In contrast to the previous VarCall models that are based on a single functional assay, we have developed a new platform to analyze the data from multiple functional assays separately and in combination. We have validated our VarCall models using 12 known pathogenic and 10 neutral variants and demonstrated their usefulness in determining the pathogenicity of BRCA2 variants that are listed as VUS or as variants with conflicting functional interpretation.

1 September 2004 in Cellular Signalling
Verified
Journal Article
Closed access
HYHye-Young Yoon
Hye-Young Yoon
KJKerry Jacques
Kerry Jacques
BNBeth Nealon
Beth Nealon
SSStacey Stauffer
Stacey Stauffer
RPRichard T Premont
Richard T Premont
PRPaul A. Randazzo
Paul A. Randazzo

2 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KHKatie E Hebron
Katie E Hebron
XWXiaolin Wan
Xiaolin Wan
JRJacob Roth
Jacob Roth
DLDavid J. Liewehr
David J. Liewehr
NSNancy E. Sealover
Nancy E. Sealover
MYMarielle E. Yohe
Marielle E. Yohe
Purpose: PAX-fusion negative rhabdomyosarcoma (FN RMS) is driven by alterations in the RAS/MAP kinase pathway and is partially responsive to MEK inhibition. Overexpression of IGF1R and its ligands is also observed in FN RMS. Preclinical and clinical studies have suggested that IGF1R is itself an important target in FN RMS. Our previous studies revealed preclinical efficacy of the MEK1/2 inhibitor, trametinib, and an IGF1R inhibitor, BMS-754807, but this combination was not pursued clinically due to intolerability in preclinical murine models. Here, we sought to identify a combination of an MEK1/2 inhibitor and IGF1R inhibitor, which would be tolerated in murine models and effective in both cell line and patient-derived xenograft models of RAS-mutant FN RMS. Experimental Design: Using proliferation and apoptosis assays, we studied the factorial effects of trametinib and ganitumab (AMG 479), a mAb with specificity for human and murine IGF1R, in a panel of RAS-mutant FN RMS cell lines. The molecular mechanism of the observed synergy was determined using conventional and capillary immunoassays. The efficacy and tolerability of trametinib/ganitumab was assessed using a panel of RAS-mutated cell-line and patient-derived RMS xenograft models. Results: Treatment with trametinib and ganitumab resulted in synergistic cellular growth inhibition in all cell lines tested and inhibition of tumor growth in four of six models of RAS-mutant RMS. The combination had little effect on body weight and did not produce thrombocytopenia, neutropenia, or hyperinsulinemia in tumor-bearing SCID beige mice. Mechanistically, ganitumab treatment prevented the phosphorylation of AKT induced by MEK inhibition alone. Therapeutic response to the combination was observed in models without a mutation in the PI3K/PTEN axis. Conclusions: We demonstrate that combined trametinib and ganitumab is effective in a genomically diverse panel of RAS-mutated FN RMS preclinical models. Our data also show that the trametinib/ganitumab combination likely has a favorable tolerability profile. These data support testing this combination in a phase I/II clinical trial for pediatric patients with relapsed or refractory RAS-mutated FN RMS.

3 December 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Directly targeting RAS is a promising approach for the treatment of RAS-altered malignancies. Recently, several groups have developed mutation-specific agents such as sotorasib and adagrasib, which directly target KRAS by covalently modifying KRAS(G12C). KRAS is commonly altered in adult malignancies, such as lung, pancreatic, and colorectal adenocarcinomas, but is less commonly altered in pediatric cancers. However, rare pediatric solid tumors harboring KRAS(G12C), HRAS(G12C), or NRAS(G12C) have been observed, including rhabdomyosarcoma and neuroblastoma tumors, as well as leukemias. The efficacy of KRAS(G12C) inhibitors in pediatric malignancies is currently unknown, and the ability of these drugs to modify HRAS(G12C) and NRAS(G12C) has not been completely characterized. In this study, we show that sotorasib, adagrasib, and the RAS-ON inhibitor RMC-6291 are effective in a neuroblastoma cell line altered by KRAS(G12C). We further demonstrated that sotorasib and adagrasib inhibited SOS-mediated guanine nucleotide exchange on HRAS(G12C) and NRAS(G12C). Sotorasib and RMC-6291 decreased ERK phosphorylation in cells expressing HRAS(G12C), KRAS(G12C), or NRAS(G12C). Importantly, sotorasib also decreased ERK phosphorylation in a NRAS(G12C)-altered cell line xenograft model; however, this treatment did not prolong survival as a single agent. These results suggest that combinations of targeted agents that include sotorasib may be required for clinical benefit in pediatric patients with HRAS(G12C)- or NRAS(G12C)-altered malignancies, in addition to those with KRAS(G12C)-altered malignancies.


17 June 2026
Verified
Other
Open access
HPHannah E. Price
Hannah E. Price
SSStacey Stauffer
Stacey Stauffer
HLHyun Lee
Hyun Lee
KIKristine A. Isanogle
Kristine A. Isanogle
YWYing Wu
Ying Wu
MYMarielle E. Yohe
Marielle E. Yohe
Establishment of a xenograft model of NRAS(G12C)-mutant leukemia